DMAC · DiaMedica Therapeutics Inc
United States · RS rating 96 · As of 2026-11-03
| Price | 10.00 USD |
|---|---|
| 1-day change | +7.6% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 93 / 95 / 81 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 38 / 45 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +0.0% |
| Market cap (USD) | $335.1M |